Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
13th Nov 2006, 16:15 GMT
Mercury hardware and MultiCore Plus SDK provide optimal balance of performance, cost, and programmability advantages over traditional supercomputing and IT offerings
Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor related news:
- Mercury, BU team says biotech app cuts processing time to minutes — bizjournals.com Health Care:Pharmaceuticals headlines
- Boston Scientific and Univ of Akron Expand License Agreement for Use of UA Polymers in Medical Devices — StratWire - Business of Healthcare NewsFeed
- New Processor For Cost-Sensitive Electronics — BIOS News: The Quality Tech Guide
- Apple teams with six major airlines to deliver iPod integration — AppleInsider
- Processor promises cost-efficient multimedia — Microprocessors, Microcontrollers and DSPs latest news on Electronicstalk
- Playstation 3 Vs XBox 360 — digg
- Amazon Biotech, Inc: Amazon Biotech Inc. Announces Union Bless Herbal Products' Application for Amendment to Approved Import Drug License to Include Amazon Biotech as Approved Supplier — Market Wire - Pharmaceuticals and Biotech
- NetBSD Live! 2007 Screenshot Walkthrough — NewsForge: NewsVac
- A power play on mercury reduction. — Environmental Health News
- Amazon Biotech Inc. Announces Union Bless Herbal Products' Application for Amendment to Approved Import Drug License to Include Amazon Biotech as Approved Supplier — ArriveNet : Health
Latest news from Bio-Technology News from StratCenter.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress
- Tanox shares soar in wake of Genentech buyout